superior industrial supply co. blue logo
0

Blog Layout

Ephedra

Dietary supplements are marketed as “performance enhancers,” “energy boosters,” “fat burners,” “street drug alternatives,” or “legal highs” on the internet, television, and in nutrition stores. With the increased attention to Ephedra, which was recently banned by the FDA, other products are quickly gaining attention. These new products, promoted as safe, ephedra-free supplements, are considered to be just as risky as Ephedra-based supplements.


EPHEDRINEIN

There are two reasons they are dangerous: 1) the supplements contain high levels of stimulants often in combination with caffeine 2) the makers of the supplements are not required to list the quantity or amount of the stimulants that are in their products.


WHAT IS A DIETARY SUPPLEMENT?

Congress defined the term “dietary supplement” in the Dietary Supplement Health and Education Act (DSHEA) of 1994. A dietary supplement is a product taken by mouth that contains a “dietary ingredient” intended to supplement the diet. The “dietary ingredients” in these products may include: vitamins, minerals, herbs or other botanicals, amino acids, and substances such as enzymes, organ tissues, glandulars, and metabolites. Dietary supplements can also be extracts or concentrates and may be found in many forms such as tablets, capsules, soft gels, gel caps, liquids, or powders. They can also be in other forms, such as a bar, but if they are, information on their label must not represent the product as a conventional food or a sole item of a meal or diet. Whatever their form may be, DSHEA places dietary supplements in a special category under the general umbrella of “foods,” not drugs, and requires that every supplement be labeled a dietary supplement.


EPHEDRA (aka epitonin, ma huang, Sida Cordifolia, Sinica) is a herbal stimulant and the main ingredient in energy-enhancing and weight loss products. Several organizations, including the American Medical Association and Health Canada, have recommended banning the sale of ephedra and many other organizations, including the National Collegiate Athletics Association, the International Olympic Committee, and the National Football League, prohibit the use of products containing ephedra.


China is a major manufacturer of ephedrine and pseudoephedrine and is one of the world’s primary exporters of both chemicals. China owns and operates ephedra farms, where ephedra grass (Ephedra Sinica) is cultivated under strict government control.


The active alkaloids, pseudoephedrine, and ephedrine are chemically extracted from the plant material and processed for pharmaceutical purposes. These chemicals are then sold domestically and internationally.


China and India are the major producers of these chemicals when extracted from the ephedra plant. In low doses, ephedrine and pseudoephedrine act as nasal decongestants. Ephedrine and pseudoephedrine are ingredients in many over-the-counter asthma medications and are also key components in illegal methamphetamine manufacturing. In high doses, the stimulant effects of these drugs can raise blood pressure and many studies have linked ephedra use to heart attacks, strokes, seizures, psychosis, insomnia, and heatstroke. Those people suffering from kidney disease, liver disease, diabetes, glaucoma, heart disease or high blood pressure, thyroid disease, emphysema or chronic bronchitis, have an enlarged prostate, are pregnant or nursing, or are taking an MAOI are advised NOT to take products containing ephedrine and pseudoephedrine.


A recent study, published in the Annals of Internal Medicine and based on information collected by the American Association of Poison Control Centers concluded: * Products containing ephedra accounted for 64% of all adverse reactions to herbs in the United States, yet these products represented only 0.82% of herbal product sales. The relative risks for an adverse reaction in persons using ephedra compared with other herbs were extremely high. Even with an extremely high estimate for ephedra’s share of the total herbal market (13.5%), the relative risks for adverse reactions among ephedra users were still 10- to 40-fold greater than the risk among users of other herbal products.


OTHER SUPPLEMENTS:

Bitter Orange: (Citrus Aurantium, aka green orange, neroli oil) contains a stimulant, synephrine that is similar to Ephedra. Given its similarities, experts believe Bitter Orange may have the same adverse effects as Ephedra. Guarana: contains 2-3 times more caffeine than coffee, other caffeine-containing supplements include kola and mate.


Green Tea Extract: Contains less caffeine than coffee, contains antioxidants, is often combined with other caffeine-based supplements.

Usnic acid: Touted as a weight loss aid, FDA issued warning about this product and possible liver damage associated with use.

Source: “The Relative Safety of Ephedra Compared with Other Herbal Products,” Stephen Bent, MD; Thomas N. Tiedt, Ph.D.; Michelle C. Odden, BS; and Michael G. Shlipak, MD, MPH; Annals of Internal Medicine, FDA, and DEA.



Other Sources:

Dietary supplement From the National Institutes of Health (National Center for Complementary and Integrative Health)
… R S T U V W X Y Z Share: On This Page Introduction What the Science …
https://nccih.nih.gov/health/ – Drugs and Supplements

Weight Loss and Complementary Health Practices: What the Science Says From the National Institutes of Health (National Center for Complementary and Integrative Health)
… risk of sunburn, particularly in light-skinned people.
https://nccih.nih.gov/health/providers/digest/weightloss-science – External Health Links

Guarana
… evidence that a specific combination product containing guarana, ephedra, and 17 other vitamins, minerals, and supplements (Metabolife- … excretion. CreatineThere is some concern that combining caffeine, ephedra, and creatine might increase the risk of serious …
https://www.nlm.nih.gov/medlineplus/druginfo/natural/935.html – Drugs and Supplements

Dietary Supplements for Weight Loss From the National Institutes of Health (National Institutes of Health, Office of Dietary Supplements) – PDF
… weight loss dietary supplements that used to contain ephedra, another stimulant- containing herb that was banned from … U.S. market in 2004. Does it work? Bitter orange might slightly increase …
https://ods.od.nih.gov/pdf/factsheets/WeightLoss-Consumer.pdf – External Health Links


By Bob Hansen January 29, 2022
Zyprexa (Olanzapine) is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder. More information/images in the Prescription Drug Brochure. When you receive Zyprexa extended-release injection, the medication is usually released slowly into your blood over a period of time. However, when you receive olanzapine extended-release injection, there is a small chance that olanzapine may be released into your blood too quickly. If this happens, you may experience a serious problem called Post-injection Delirium Sedation Syndrome (PDSS). If you develop PDSS, you may experience dizziness, confusion, difficulty thinking clearly, anxiety, irritability, aggressive behavior, weakness, slurred speech, difficulty walking, muscle stiffness or shaking, seizures, drowsiness, and coma (loss of consciousness for a period of time). You are most likely to experience these symptoms during the first 3 hours after you receive the medication. You will receive Zyprexa extended-release injection in a hospital, clinic, or another medical facility where you can receive emergency medical treatment if it is needed. You will need to remain in the facility for at least 3 hours after you receive the medication. While you are in the clinic, the medical staff will watch you closely for signs of PDSS. When you are ready to leave the facility, you will need a responsible person to be with you, and you should not drive a car or operate machinery for the rest of the day. Get emergency medical help right away if you experience any symptoms of PDSS after you leave the facility. A program has been set up to help people receive Zyprexa extended-release injection safely. You will need to register and agree to the rules of this program before you receive olanzapine extended-release injection. Your doctor, the pharmacy that dispenses your medication, and the medical facility where you receive your medication will also need to register. Ask your doctor if you have any questions about this program. For people being treated with olanzapine extended-release injection or Zyprexa injection: Studies have shown that older adults with dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and that may cause changes in mood and personality) who take antipsychotics (medications for mental illness) such as olanzapine have an increased chance of death during treatment. Older adults with dementia may also have a greater chance of having a stroke or mini-stroke during treatment. Olanzapine injection and olanzapine extended-release injection are not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia. Talk to the doctor who prescribed this medication if you, a family member, or someone you care for has dementia and is being treated with olanzapine injection or olanzapine extended-release injection. For more information visit the FDA website: http://www.fda.gov/Drugs Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with olanzapine extended-release injection and each time you receive an injection. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer’s website to obtain the Medication Guide. extended-release injection, the medication is usually released slowly into your blood over a period of time. However, when you receive olanzapine extended-release injection, there is a small chance that olanzapine may be released into your blood too quickly. If this happens, you may experience a serious problem called Post-injection Delirium Sedation Syndrome (PDSS). If you develop PDSS, you may experience dizziness, confusion, difficulty thinking clearly, anxiety, irritability, aggressive behavior, weakness, slurred speech, difficulty walking, muscle stiffness or shaking, seizures, drowsiness, and coma (loss of consciousness for a period of time). You are most likely to experience these symptoms during the first 3 hours after you receive the medication. You will receive olanzapine extended-release injection in a hospital, clinic, or another medical facility where you can receive emergency medical treatment if it is needed. You will need to remain in the facility for at least 3 hours after you receive the medication. While you are in the clinic, the medical staff will watch you closely for signs of PDSS. When you are ready to leave the facility, you will need a responsible person to be with you, and you should not drive a car or operate machinery for the rest of the day. Get emergency medical help right away if you experience any symptoms of PDSS after you leave the facility. A program has been set up to help people receive olanzapine extended-release injection safely. You will need to register and agree to the rules of this program before you receive olanzapine extended-release injection. Your doctor, the pharmacy that dispenses your medication, and the medical facility where you receive your medication will also need to register. Ask your doctor if you have any questions about this program. For people being treated with olanzapine extended-release injection or olanzapine injection: Studies have shown that older adults with dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and that may cause changes in mood and personality) who take antipsychotics (medications for mental illness) such as olanzapine have an increased chance of death during treatment. Older adults with dementia may also have a greater chance of having a stroke or mini-stroke during treatment. Olanzapine injection and olanzapine extended-release injection are not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia. Talk to the doctor who prescribed this medication if you, a family member, or someone you care for has dementia and is being treated with olanzapine injection or olanzapine extended-release injection. For more information visit the FDA website: http://www.fda.gov/Drugs  Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with olanzapine extended-release injection and each time you receive an injection. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer’s website to obtain the Medication Guide.
By Bob Hansen January 29, 2022
Zoloft (Sertraline) is included in the class of drugs called selective serotonin reuptake inhibitors (SSRIs). This class of drugs is used to treat depression, anxiety, and other mood disorders.
By Bob Hansen January 29, 2022
Zanaflex (Tizanidine) is a short-acting muscle relaxer. Tizanidine is used to relieve the spasms and increased muscle tone caused by multiple sclerosis (MS, a disease in which the nerves do not function properly and patients may experience weakness, numbness, loss of muscle coordination and problems with vision, speech, and bladder control), stroke, or brain or spinal injury. Tizanidine is in a class of medications called skeletal muscle relaxants. It works by slowing action in the brain and nervous system to allow the muscles to relax. Tizanidine comes as a tablet and a capsule to take by mouth. It is usually taken consistently either always with or always without food two or three times a day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take tizanidine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Tizanidine capsules may be opened and sprinkled on soft foods such as applesauce. Talk to your doctor before opening the capsules because the effects of the medication, when used in this manner, may be different than when swallowing the capsule whole. The medication in the capsule is absorbed differently by the body than the medication in the tablet, so one product cannot be substituted for the other. Each time you have your prescription filled, look at the tablets or capsules in the bottle and make sure that you have received the right product. If you think you received the wrong medication, talk to your doctor or pharmacist right away. Your doctor will probably start you on a low dose of tizanidine and gradually increase your dose, depending on your response to this medication.  Do not stop taking tizanidine without talking to your doctor. If you suddenly stop taking tizanidine, your heart may beat faster and you may have increased blood pressure or tightness in your muscles. Your doctor will probably decrease your dose gradually.
More Posts
Share by: